GLP-1 Based Therapeutics Summit
Presentation details:
Advancing Enobosarm, An Oral Novel Selective Androgen Receptor Modulator (SARM), to Avoid Muscle Loss and Augment Fat Loss When Combined with a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Drugs for Potentially Higher Quality Weight Loss
Date: Thursday, May 16, 2024
Start and end time: 9:00 AM – 9:30 AM Eastern Daylight Time
- Highlighting the concerns that (i) muscle loss caused by GLP-1 receptor agonists may be partly responsible for weight loss plateau, (ii) upon stopping GLP-1 RA, the fat and weight rebound regain, and (iii) such muscle loss may accelerate the development of frailty in at-risk older sarcopenic obese patients who are at risk for physical function limitations
- Presenting the 5 clinical studies of enobosarm in older patients and in patients with a cancer induced starvation-like state that provide a strong scientific rationale for the ongoing Phase 2b enobosarm + GLP-1 RA clinical study
- Providing supporting evidence that enobosarm in combination with a GLP-1 RA may potentially augment the fat reduction with higher quality total weight loss while preserving muscle and physical function
Additional information on the meeting can be found on the GLP-1 Based Therapeutics Summit website: https://glp-1-based-therapeutics.com/